pharmaceutical investing Albireo Announces FDA Clearance of IND to Commence Phase 2 Trial of Elobixibat
pharmaceutical investing FDA Grants Rare Pediatric Disease Designation to A4250; Albireo Eligible to Apply for Priority Review Voucher
Oreterra Announces Closing of Final Tranche of $9.7 Million Oversubscribed and Upsized Non-Brokered Private Placement
SAGA Metals Reports Assay Intercepts Including 52.05% Fe?O?, 7.21% TiO?, 0.375% V?O? from 2026 Drilling at Trapper South, Radar Critical Minerals Project in Labrador
